Abstract
Most hearing loss results from lesions of the sensory cells and/or neurons of the auditory portion of the inner ear. To date, only the cochlear implantation offers long-term hearing-aid benefit, but still with limited performance and expensive cost. While the underlying causes of deafness are not clear, the death or hair cells and/or neurons and the loss of neuronal contacts are key pathological features. Pinpointing molecular events that control cell death in the cochlea is critical for the development of new strategies to prevent and treat deafness, whether in combination or not with cochlear implant therapy.
Keywords: cochlea, cell death, ototoxicity, noise trauma, neuroprotection, trophic factors
Current Pharmaceutical Design
Title: Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Volume: 11 Issue: 17
Author(s): F. Lallemend, P. P. Lefebvre, G. Hans, G. Moonen and B. Malgrange
Affiliation:
Keywords: cochlea, cell death, ototoxicity, noise trauma, neuroprotection, trophic factors
Abstract: Most hearing loss results from lesions of the sensory cells and/or neurons of the auditory portion of the inner ear. To date, only the cochlear implantation offers long-term hearing-aid benefit, but still with limited performance and expensive cost. While the underlying causes of deafness are not clear, the death or hair cells and/or neurons and the loss of neuronal contacts are key pathological features. Pinpointing molecular events that control cell death in the cochlea is critical for the development of new strategies to prevent and treat deafness, whether in combination or not with cochlear implant therapy.
Export Options
About this article
Cite this article as:
Lallemend F., Lefebvre P. P., Hans G., Moonen G. and Malgrange B., Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies, Current Pharmaceutical Design 2005; 11 (17) . https://dx.doi.org/10.2174/1381612054367346
DOI https://dx.doi.org/10.2174/1381612054367346 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma
Current Cancer Drug Targets Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Current Topics in Medicinal Chemistry Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Nanoparticles in Cancer
Current Radiopharmaceuticals Isolation, Characterization and Preliminary Cytotoxic and Antifungal Evaluations of Novel Lancifoliate Isolated from Methanol Extract of <i>Conocarpus lancifolius</i>
Anti-Cancer Agents in Medicinal Chemistry Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design